[Everolimus inhibits malignant phenotype of erdafitinib-resistant bladder cancer cells through the p70S6K/PI3K/MAPK signaling pathway].

Propranolol attenuates the malignant biological behaviors of renal cancer cells partly through modulation of the IL-6/PI3K/AKT signaling axis

Objective To investigate the effects of propranolol on the malignant biological behaviours of renal cancer cells and explore the potential involvement of the IL-6/PI3K/AKT signalling axis. Methods 786-O and Caki-2 ccRCC cells were treated with gradient propranolol, followed by CCK-8, wound-healing, Transwell and flow c...

Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer

Background Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major challenge in non-small cell lung cancer (NSCLC) treatment. Although ascomycin (FK520) has demonstrated some antitumor activity, its potential in overcoming osimertinib resistance has not been fully character...

Sophocarpine Inhibits Proliferation and Triggers Apoptosis in Breast Cancer Cells by Modulating the miR-21/PTEN/AKT and ERK1/2 Signaling Networks

Findings identify SC as a potential structural scaffold exhibiting preliminary anti-tumor activity against breast cancer cells, at least in part, through modulating miR-21 and inhibition of the AKT/mTOR/ERK1/2 survival network.

FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer.

These findings identify the FOXD1/β-catenin/DARS2 axis as a potential therapeutic target for overcoming cisplatin resistance in BLCA clinically and promote cisplatin resistance in BLCA.

Birinapant enhances cisplatin sensitivity in epithelial ovarian cancer through modulation of apoptotic and survival signaling pathways

The findings suggest that TNF-α responsiveness, cIAP1 (BIRC2)-related signaling, and the ability of cancer cells to activate apoptotic pathways, particularly caspase-8, may serve as potential biomarkers for identifying tumors more likely to respond to Birinapant-based combination therapies.

[Anwulignan inhibits malignant phenotypes of gastric cancer cells by antagonizing activation of the JAK1/STAT3 signaling pathway].